DXIV - ETF AI Analysis

Top Page

Dimensional International Vector Equity ETF (DXIV)

Rating:62Neutral

Price Target:―

The Dimensional International Vector Equity ETF (DXIV) has a solid overall rating, driven by strong contributions from holdings like ASML and Novartis. ASML stands out with its robust financial performance, strategic growth initiatives, and positive momentum, while Novartis benefits from strong financials and a focus on innovation. However, weaker holdings like Bayer, which faces financial challenges and valuation concerns, slightly weigh on the fund's overall score. A key risk factor is the ETF's exposure to specific sectors or regions that may amplify volatility.

Positive Factors

Strong Top Holdings

Several key holdings, such as ASML Holding and Orange SA, have delivered strong year-to-date performance, supporting the ETF's overall returns.

Global Diversification

The ETF has exposure to multiple countries, including Japan, the UK, and Germany, reducing reliance on any single market.

Reasonable Expense Ratio

With a 0.3% expense ratio, the fund offers relatively low costs compared to actively managed alternatives.

Negative Factors

Underperforming Holding

TotalEnergies SE, one of the top holdings, has shown negative year-to-date performance, which could drag on returns.

Sector Concentration Risk

Industrials and Financials make up a significant portion of the portfolio, increasing sensitivity to sector-specific downturns.

Limited U.S. Exposure

The ETF allocates only 11.78% to U.S. companies, which may limit participation in the strong performance of the U.S. market.

DXIV vs. SPDR S&P 500 ETF (SPY)

AUM122.80M

RegionDeveloped Markets

Expense Ratio0.30%

Beta0.62

IssuerDimensional

Inception DateSep 12, 2024

Dividend Yield2.5%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume7,640

30 Day Avg. Volume5,904

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

80.40

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2622

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DXIV Summary

The Dimensional International Vector Equity ETF (DXIV) is an investment fund that gives you access to a wide range of companies from around the world, focusing on markets outside the United States. It includes stocks from both developed and emerging markets, with top holdings like TotalEnergies and Novartis. This ETF is designed for investors looking to diversify globally and potentially benefit from long-term growth by investing in companies across different sectors and regions. However, since it invests heavily in international markets, its performance can be affected by global economic and currency fluctuations.

How much will it cost me?The Dimensional International Vector Equity ETF (DXIV) has an expense ratio of 0.3%, which means you’ll pay $3 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is actively managed, focusing on a refined selection of international stocks to enhance potential returns.

What would affect this ETF?DXIV's focus on developed markets outside the U.S. and its exposure to sectors like Industrials, Financials, and Consumer Cyclical could benefit from global economic growth and increased infrastructure spending. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance. The ETF's top holdings in energy and healthcare companies may also be influenced by fluctuating commodity prices and evolving healthcare policies.

DXIV Top 10 Holdings

The Dimensional International Vector Equity ETF (DXIV) leans heavily on developed markets outside the U.S., with a diverse mix of sectors and standout names driving its performance. Healthcare giants like Roche and AstraZeneca are rising stars, benefiting from strong pipelines and bullish momentum, while ASML Holding shines in the technology space with robust growth initiatives. On the flip side, Shell and Nestlé are lagging slightly, with mixed technical trends and valuation concerns holding them back. The fund’s broad sector exposure, from financials to consumer staples, ensures balanced positioning, but healthcare and energy seem to be key drivers of its story.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
TTE	TotalEnergies SE	0.96%	$1.18M	€120.47B	6.95%	78 Outperform
NVS	Novartis	0.79%	$970.99K	$265.73B	41.46%	80 Outperform
BHP	BHP Group Ltd	0.69%	$845.95K	AU$231.44B	21.90%	68 Neutral
SHEL	Shell	0.61%	$748.53K	$207.84B	18.93%	78 Outperform
ROG	Roche Holding AG	0.58%	$716.49K	CHF263.28B	52.00%	73 Outperform
ASML	ASML Holding	0.58%	$715.68K	$406.24B	47.54%	81 Outperform
AZN	AstraZeneca	0.58%	$710.58K	$287.39B	38.97%	79 Outperform
ORA	ORANGE SA	0.56%	$684.86K	€37.36B	47.04%	65 Neutral
NESN	Nestlé SA	0.53%	$657.74K	CHF196.70B	18.81%	71 Outperform
BAYN	Bayer	0.52%	$640.50K	€35.31B	91.35%	54 Neutral

DXIV Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

62.14

Positive

100DMA

61.14

Positive

200DMA

57.56

Positive

Market Momentum

MACD

0.79

Negative

RSI

72.07

Negative

STOCH

84.35

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DXIV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 63.54, equal to the 50-day MA of 62.14, and equal to the 200-day MA of 57.56, indicating a bullish trend. The MACD of 0.79 indicates Negative momentum. The RSI at 72.07 is Negative, neither overbought nor oversold. The STOCH value of 84.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DXIV.

DXIV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DXIV	―	―	$122.80M	0.30%	―
DFSI	―	―	$915.27M	0.24%	―
SEIE	―	―	$864.55M	0.50%	―
FYLD	―	―	$484.75M	0.59%	―
AVSD	―	―	$410.22M	0.23%	―
TXUE	―	―	$302.17M	0.65%	―

Performance Comparison

DXIV

Dimensional International Vector Equity ETF

65.18

18.15

38.59%

DFSI

Dimensional International Sustainability Core 1 ETF

―

SEIE

SEI Select International Equity ETF

―

FYLD

Cambria Foreign Shareholder Yield ETF

―

AVSD

Avantis Responsible International Equity ETF

―

TXUE

Thornburg International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents